FDA approves Amgen migraine drug, price set at $6900 per year
Thursday, 17 May 2018
(Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's drug Aimovig for the prevention of migraine headaches in adults.
Credit: Wochit - Published
on May 18, 2018 < > Embed
The FDA approved a new migraine drug on Thursday. Aimovig, known generically as erenumab, is the first drug shown to stop migraine headaches before they start. The drug would be approved for patients who have tried other drugs and found no relief. In studies, it did not entirely prevent migraines,... ▶ New Drug Prevents Migraines Before They Start 00:49
You Might Like
Recent related news from verified sources
Trading in Trevena shares halted as FDA reviews company's pain treatment drug Trading in the shares of Trevena Inc (NASDAQ:TRVN) were halted on Thursday because the US Food and Drug Administration’s is reviewing its pain drug for adult... Proactive Investors 5 days ago - Business
Cannpal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications CannPal Animal Therapeutics Ltd (ASX:CP1) director Max Johnston has demonstrated his confidence in the company’s cannabis-derived medications for animals by... Proactive Investors 1 week ago - Business
AcelRx Pharmaceuticals shares soar following FDA advisory committee’s approval vote for Dsuvia AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) shares are on the rise following an approval vote from the US Food and Drug Administration advisory committee on its... Proactive Investors 1 day ago - Business Cyclopharm eyes faster market entry for Technegas following positive US FDA meeting Cyclopharm Limited (ASX:CYC) has opened up an alternative pathway for the approval of its Technegas generator following a meeting with the United States Food and... Proactive Investors 5 days ago - Business Tweets about this
Other recent news in Health
Recent related videos from verified sources
Eli Lilly to Offer Breakthrough Migraine Drug for Free 01:58
Relief for migraine suffers may, at long last, be imminent. With the FDA approving Eli Lilly's Emgality drug, Christi Shaw, president of Lilly Bio-Medicines, expounded on the drug's potential efficacy...
Credit: Cheddar Inc. - Published 3 weeks ago